You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarisoprodol
Accession NumberDB00395  (APRD00417)
TypeSmall Molecule
GroupsApproved
DescriptionA centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)
Structure
Thumb
Synonyms
(+-)-2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
(1-Methylethyl)carbamic acid 2-(((aminocarbonyl)oxy)methyl)-2-methylpentyl ester
(RS)-2-{[(aminocarbonyl)oxy]methyl}-2-methylpentyl isopropylcarbamate
2-Methyl-2-propyl-1,3-propanediol carbamate isopropylcarbamate
2-Methyl-2-propyltrimethylene carbamate isopropylcarbamate
Carbamic acid 2-isopropylcarbamoyloxymethyl-2-methyl-pentyl ester
Carisoprodate
Carisoprodol
Carisoprodolum
Isobamate
Isomeprobamate
Isopropyl meprobamate
Isopropylmeprobamate
N-Isopropy-2-methyl-2-propyl-1,3-propanediol dicarbamate
Someprobamate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarisoprodolTablet250 mg/1OralWallace Pharmaceuticals Inc.2010-07-01Not applicableUs
SomaTablet350 mg/1OralMeda Pharmaceuticals Inc.1959-07-01Not applicableUs
SomaTablet250 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-09-01Not applicableUs
SomaTablet250 mg/1OralMeda Pharmaceuticals Inc.2007-09-01Not applicableUs
SomaTablet250 mg/1OralSTAT Rx USA LLC2007-09-01Not applicableUs
SomaTablet250 mg/1OralRebel Distributors Corp2007-09-01Not applicableUs
Soma Tablets 350mgTablet350 mgOralCarter Horner Corp.1962-12-312003-03-14Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CarisoprodolTablet350 mg/1OralScie Gen Pharmaceuticals, Inc.2014-01-27Not applicableUs
CarisoprodolTablet350 mg/1OralSun Pharmaceutical Industries Limited2007-02-27Not applicableUs
CarisoprodolTablet350 mg/1OralPreferred Pharmaceuticals, Inc.2015-05-01Not applicableUs
CarisoprodolTablet350 mg/1OralAidarex Pharmaceuticals LLC2010-08-30Not applicableUs
CarisoprodolTablet350 mg/1OralWest ward Pharmaceutical Corp1996-01-24Not applicableUs
CarisoprodolTablet350 mg/1OralSTAT Rx USA LLC1996-01-24Not applicableUs
CarisoprodolTablet350 mg/1OralPhysicians Total Care, Inc.1996-04-04Not applicableUs
CarisoprodolTablet350 mg/1OralDispensing Solutions, Inc.1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-02-20Not applicableUs
CarisoprodolTablet350 mg/1Oralbryant ranch prepack1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralApotheca Inc.1991-10-17Not applicableUs
CarisoprodolTablet350 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-02-27Not applicableUs
CarisoprodolTablet350 mg/1OralH.J. Harkins Company, Inc.1996-01-24Not applicableUs
CarisoprodolTablet350 mg/1OralPd Rx Pharmaceuticals, Inc.1987-11-01Not applicableUs
CarisoprodolTablet350 mg/1OralKeltman Pharmaceuticals Inc.2007-08-10Not applicableUs
CarisoprodolTablet350 mg/1OralAurobindo Pharma Limited2009-08-06Not applicableUs
CarisoprodolTablet350 mg/1OralBlenheim Pharmacal, Inc.2012-10-15Not applicableUs
CarisoprodolTablet350 mg/1OralREMEDYREPACK INC.2013-05-09Not applicableUs
CarisoprodolTablet350 mg/1OralRx Change Co.2010-07-01Not applicableUs
CarisoprodolTablet350 mg/1OralUnit Dose Services2007-02-27Not applicableUs
CarisoprodolTablet350 mg/1OralProficient Rx LP2014-06-01Not applicableUs
CarisoprodolTablet350 mg/1OralBionpharma Inc.2015-04-01Not applicableUs
CarisoprodolTablet350 mg/1OralWatson Laboratories, Inc.1987-11-01Not applicableUs
CarisoprodolTablet350 mg/1OralPd Rx Pharmaceuticals, Inc.1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralDispensing Solutions, Inc.1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralRed Pharm Drug Inc.1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-06-01Not applicableUs
CarisoprodolTablet350 mg/1OralMutual Pharmaceutical Company, Inc.1991-10-17Not applicableUs
CarisoprodolTablet350 mg/1Oralbryant ranch prepack1987-11-01Not applicableUs
CarisoprodolTablet350 mg/1OralCarlsbad Technology, Inc.2014-01-27Not applicableUs
CarisoprodolTablet350 mg/1OralRebel Distributors Corp2007-02-27Not applicableUs
CarisoprodolTablet350 mg/1OralA S Medication Solutions Llc2007-02-27Not applicableUs
CarisoprodolTablet350 mg/1OralGolden State Medical Supply, Inc.2014-02-20Not applicableUs
CarisoprodolTablet350 mg/1OralPreferred Pharmaceuticals, Inc.2011-06-15Not applicableUs
CarisoprodolTablet250 mg/1OralAurobindo Pharma Limited2016-11-08Not applicableUs
CarisoprodolTablet350 mg/1OralBlenheim Pharmacal, Inc.2011-01-31Not applicableUs
CarisoprodolTablet350 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1987-11-01Not applicableUs
CarisoprodolTablet350 mg/1OralNorthwind Pharmaceuticals2014-06-01Not applicableUs
CarisoprodolTablet350 mg/1OralProficient Rx LP1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralLife Line Home Care Services, Inc1987-11-01Not applicableUs
CarisoprodolTablet350 mg/1OralQualitest Pharmaceuticals1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralMedsource Pharmaceuticals2007-02-27Not applicableUs
CarisoprodolTablet350 mg/1OralCardinal Health2010-01-15Not applicableUs
CarisoprodolTablet350 mg/1OralAphena Pharma Solutions Tennessee, Llc1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralNu Care Pharmaceuticals, Inc.2010-07-01Not applicableUs
CarisoprodolTablet350 mg/1OralA S Medication Solutions Llc1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralDIRECT RX2016-04-01Not applicableUs
CarisoprodolTablet350 mg/1OralA S Medication Solutions Llc2007-02-27Not applicableUs
CarisoprodolTablet350 mg/1OralDIRECT RX2014-01-01Not applicableUs
CarisoprodolTablet350 mg/1OralPreferred Pharmaceuticals, Inc.2013-11-13Not applicableUs
CarisoprodolTablet350 mg/1OralSTAT Rx USA LLC1996-01-24Not applicableUs
CarisoprodolTablet350 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1996-01-24Not applicableUs
CarisoprodolTablet350 mg/1OralMirror Pharmaceuticals LLC2011-08-22Not applicableUs
CarisoprodolTablet350 mg/1Oralbryant ranch prepack1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralOrient Pharma Co., Ltd.2015-06-01Not applicableUs
CarisoprodolTablet350 mg/1OralAmerican Health Packaging2010-01-15Not applicableUs
CarisoprodolTablet350 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-07-01Not applicableUs
CarisoprodolTablet350 mg/1OralBlenheim Pharmacal, Inc.2011-02-02Not applicableUs
CarisoprodolTablet350 mg/1OralREMEDYREPACK INC.2013-04-032016-10-13Us
CarisoprodolTablet350 mg/1OralCardinal Health2010-10-08Not applicableUs
CarisoprodolTablet350 mg/1OralA S Medication Solutions Llc1997-09-08Not applicableUs
CarisoprodolTablet350 mg/1OralRising Pharmaceuticals, Inc.2010-07-01Not applicableUs
CarisoprodolTablet350 mg/1OralWest Ward Pharmaceuticals Corp1996-01-24Not applicableUs
CarisoprodolTablet350 mg/1OralVensun Pharmaceuticals, Inc.2014-07-31Not applicableUs
Carisoprodol Immediate ReleaseTablet250 mg/1OralVensun Pharmaceuticals, Inc2015-11-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CarisomaNot Available
GencariGenovate
GenesafeGenovate
HiraninHwang's
ListaflexFinadiet
SanomaNot Available
TensaprinNewport
Brand mixtures
NameLabellerIngredients
Carisoprodol and AspirinEon Labs, Inc.
Carisoprodol, Aspirin and Codeine PhosphateEon Labs, Inc.
SaltsNot Available
Categories
UNII21925K482H
CAS number78-44-4
WeightAverage: 260.33
Monoisotopic: 260.173607266
Chemical FormulaC12H24N2O4
InChI KeyOFZCIYFFPZCNJE-UHFFFAOYSA-N
InChI
InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)
IUPAC Name
2-[(carbamoyloxy)methyl]-2-methylpentyl N-(propan-2-yl)carbamate
SMILES
CCCC(C)(COC(N)=O)COC(=O)NC(C)C
Pharmacology
IndicationFor the relief of discomfort associated with acute, painful, musculoskeletal conditions.
Structured Indications
PharmacodynamicsCarisoprodol is used as a skeletal muscle relaxant. One of its metabolites, meprobamate, is available as an anxiolytic agent.
Mechanism of actionCarisoprodol is a central nervous system depressant that acts as a sedative and skeletal muscle relaxant. Rather than acting directly on skeletal muscle, carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. Its exact mechanism of action is not yet known.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding60%
Metabolism

Hepatic. Metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19.

Route of eliminationCarisoprodol is eliminated by both renal and non-renal routes.
Half life8 hours
Clearance
  • oral cl=0.772 L/hour/kg [Women]
  • oral cl=0.38 L/hour/kg [Men]
ToxicitySymptoms of overdose include drowsiness, giddiness, nausea, indigestion, or rash. Other adverse effects attributed to therapeutic use of carisoprodol include dizziness, irritability, insomnia, diplopia, temporary loss of vision, ataxia, weakness, headache, and dysarthria. Non-CNS adverse effects include gastrointestinal complaints, tachycardia, and postural hypotension. Patients sensitive to sulfites or tartrazine may experience wheezing, allergic rashes including erythema multiforme, or anaphylaxis after using some preparations of carisoprodol which contain such additives
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Carisoprodol.Experimental
AbirateroneThe metabolism of Carisoprodol can be decreased when combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Carisoprodol.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Carisoprodol.Approved
Acetylsalicylic acidThe serum concentration of the active metabolites of Carisoprodol can be increased when Carisoprodol is used in combination with Acetylsalicylic acid.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Carisoprodol.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Carisoprodol.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Carisoprodol.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Carisoprodol.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Carisoprodol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carisoprodol.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Carisoprodol.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Carisoprodol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Carisoprodol.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Carisoprodol.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carisoprodol.Approved, Investigational
ArmodafinilThe metabolism of Carisoprodol can be decreased when combined with Armodafinil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Carisoprodol.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Carisoprodol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Carisoprodol.Vet Approved
AzelastineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Carisoprodol.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Carisoprodol.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Carisoprodol.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Carisoprodol.Approved
BortezomibThe metabolism of Carisoprodol can be decreased when combined with Bortezomib.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Carisoprodol.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Carisoprodol.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carisoprodol.Approved, Investigational
BuprenorphineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Carisoprodol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carisoprodol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Carisoprodol.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Carisoprodol.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Carisoprodol.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Carisoprodol.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Carisoprodol.Approved, Illicit, Vet Approved
CarbamazepineThe metabolism of Carisoprodol can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Carisoprodol.Illicit, Vet Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Carisoprodol.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Carisoprodol.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Carisoprodol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Carisoprodol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Carisoprodol.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Carisoprodol.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Carisoprodol.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carisoprodol.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Carisoprodol.Approved
CholecalciferolThe metabolism of Carisoprodol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Carisoprodol can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carisoprodol.Approved, Vet Approved
CitalopramThe metabolism of Carisoprodol can be decreased when combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Carisoprodol.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Carisoprodol.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Carisoprodol.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Carisoprodol.Approved, Illicit
ClotrimazoleThe metabolism of Carisoprodol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Carisoprodol.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Carisoprodol.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Carisoprodol.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carisoprodol.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Carisoprodol can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carisoprodol.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dapoxetine.Investigational
DelavirdineThe metabolism of Carisoprodol can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Carisoprodol.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Carisoprodol.Approved
DesipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Carisoprodol.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Carisoprodol.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Carisoprodol.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Carisoprodol.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Carisoprodol.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Carisoprodol.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Carisoprodol.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Carisoprodol.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carisoprodol.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Carisoprodol.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Carisoprodol.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Carisoprodol.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Carisoprodol.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Carisoprodol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Carisoprodol.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Carisoprodol.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Carisoprodol.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Carisoprodol.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Carisoprodol can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Carisoprodol can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Carisoprodol.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carisoprodol.Approved
EthanolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carisoprodol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Carisoprodol.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Carisoprodol.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Carisoprodol.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Carisoprodol.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Carisoprodol.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Carisoprodol.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Carisoprodol.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Carisoprodol.Illicit, Vet Approved
EtravirineThe metabolism of Carisoprodol can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Carisoprodol.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Carisoprodol.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flibanserin.Approved
FluconazoleThe metabolism of Carisoprodol can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Carisoprodol.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Carisoprodol.Approved, Illicit
FluoxetineThe metabolism of Carisoprodol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Carisoprodol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carisoprodol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Carisoprodol.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Carisoprodol.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Carisoprodol can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe metabolism of Carisoprodol can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Carisoprodol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Carisoprodol.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Carisoprodol is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Carisoprodol.Approved, Illicit
GemfibrozilThe metabolism of Carisoprodol can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Carisoprodol.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Carisoprodol.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carisoprodol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Carisoprodol.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Carisoprodol.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Carisoprodol.Approved
HydrocodoneCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carisoprodol.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Carisoprodol can be decreased when combined with Indinavir.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Carisoprodol.Approved, Vet Approved
IsoniazidThe metabolism of Carisoprodol can be decreased when combined with Isoniazid.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Carisoprodol.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Carisoprodol.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Carisoprodol.Approved
KetoconazoleThe metabolism of Carisoprodol can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Carisoprodol.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Carisoprodol.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Carisoprodol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Carisoprodol.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Carisoprodol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Carisoprodol.Illicit
LopinavirThe metabolism of Carisoprodol can be increased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carisoprodol.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Carisoprodol.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Carisoprodol.Investigational
LuliconazoleThe serum concentration of Carisoprodol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Carisoprodol can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carisoprodol.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Carisoprodol.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Carisoprodol.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Carisoprodol.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carisoprodol.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carisoprodol.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Carisoprodol.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Carisoprodol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Carisoprodol.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Carisoprodol.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Carisoprodol.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Carisoprodol.Approved
MethotrimeprazineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Carisoprodol.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Carisoprodol.Approved
MetyrosineCarisoprodol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Carisoprodol.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Investigational
MirtazapineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe metabolism of Carisoprodol can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Carisoprodol can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Carisoprodol.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Carisoprodol.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Carisoprodol.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Carisoprodol can be decreased when combined with Nelfinavir.Approved
NicardipineThe metabolism of Carisoprodol can be decreased when combined with Nicardipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Carisoprodol.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Carisoprodol.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Carisoprodol.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Carisoprodol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Carisoprodol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Carisoprodol.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Carisoprodol.Approved, Illicit
OrphenadrineCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Carisoprodol.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carisoprodol.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Carisoprodol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Carisoprodol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carisoprodol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Carisoprodol.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carisoprodol.Approved
PantoprazoleThe metabolism of Carisoprodol can be decreased when combined with Pantoprazole.Approved
ParaldehydeCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Carisoprodol.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carisoprodol.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
PerazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Carisoprodol.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Carisoprodol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Carisoprodol.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Carisoprodol.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Carisoprodol.Approved
PhenytoinThe metabolism of Carisoprodol can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Carisoprodol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carisoprodol.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pomalidomide.Approved
PramipexoleCarisoprodol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Carisoprodol.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Carisoprodol.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Carisoprodol.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Carisoprodol.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Carisoprodol.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carisoprodol.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Carisoprodol.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Carisoprodol.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Carisoprodol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Carisoprodol.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carisoprodol.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Carisoprodol.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Carisoprodol.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carisoprodol.Approved
RacloprideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carisoprodol.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carisoprodol.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Carisoprodol.Approved
RifampicinThe metabolism of Carisoprodol can be increased when combined with Rifampicin.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Carisoprodol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Carisoprodol.Vet Approved
RopiniroleCarisoprodol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carisoprodol.Approved
RotigotineCarisoprodol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Carisoprodol.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Carisoprodol.Experimental
Sage 547The risk or severity of adverse effects can be increased when Carisoprodol is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carisoprodol.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Carisoprodol.Approved, Withdrawn
SertralineThe metabolism of Carisoprodol can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carisoprodol.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
St. John's WortThe serum concentration of the active metabolites of Carisoprodol can be increased when Carisoprodol is used in combination with St. John's Wort.Nutraceutical
StiripentolThe metabolism of Carisoprodol can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carisoprodol.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carisoprodol.Approved
SuvorexantCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Carisoprodol.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Carisoprodol.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Carisoprodol.Investigational
ThalidomideCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carisoprodol.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Carisoprodol.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Carisoprodol.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Carisoprodol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tiapride.Investigational
TiclopidineThe metabolism of Carisoprodol can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Carisoprodol.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Carisoprodol.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Carisoprodol.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Carisoprodol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Carisoprodol.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carisoprodol.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Carisoprodol.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Carisoprodol.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carisoprodol.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Carisoprodol.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Carisoprodol is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Carisoprodol.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Carisoprodol can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Carisoprodol.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Carisoprodol.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carisoprodol.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Carisoprodol.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Carisoprodol.Vet Approved
ZolpidemCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Carisoprodol.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Carisoprodol.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carisoprodol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.
References
Synthesis Reference

Berger, F.M. and Ludwig, B.J.; U S . Patent 2,937,119; May 17,1960; assigned to Carter
Products, Inc.

General References
  1. Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004 Sep;26(9):1355-67. [PubMed:15530999 ]
  2. Chou R, Peterson K, Helfand M: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. [PubMed:15276195 ]
  3. Littrell RA, Hayes LR, Stillner V: Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J. 1993 Jul;86(7):753-6. [PubMed:8322081 ]
External Links
ATC CodesM03BA52M03BA02M03BA72
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (84.9 KB)
MSDSDownload (73.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9626
Blood Brain Barrier+0.9679
Caco-2 permeable-0.5533
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.8014
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.9519
CYP450 2C9 substrateNon-substrate0.9041
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6418
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8659
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6872
BiodegradationNot ready biodegradable0.973
Rat acute toxicity2.3261 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9957
hERG inhibition (predictor II)Non-inhibitor0.9362
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Meda pharmaceuticals meda pharmaceuticals inc
  • Able laboratories inc
  • Actavis totowa llc
  • Advent pharmaceuticals inc
  • Aurobindo pharma ltd
  • Concord laboratories inc
  • Corepharma llc
  • Mutual pharmaceutical co inc
  • Pioneer pharmaceuticals inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Schering corp sub schering plough corp
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral250 mg/1
TabletOral350 mg/1
TabletOral350 mg
Prices
Unit descriptionCostUnit
Soma 350 mg tablet5.75USD tablet
Soma Compound 200-325 mg tablet4.58USD tablet
Soma 250 mg tablet3.24USD tablet
Carisoprodol powder1.17USD g
Carisoprodol 350 mg tablet0.57USD tablet
Flexall plus gel0.08USD g
Flexall 16% gel0.06USD g
Flexall 7% gel0.05USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point89-91Berger, F.M. and Ludwig, B.J.; U S . Patent 2,937,119; May 17,1960; assigned to Carter Products, Inc.
water solubility300 mg/L (at 25 °C)MERCK INDEX (1996)
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.792 mg/mLALOGPS
logP1.76ALOGPS
logP1.92ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)15.06ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area90.65 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity67.1 m3·mol-1ChemAxon
Polarizability28.77 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4l-9200000000-84ceb4ca447a62939b63View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as monocarboxylic acids and derivatives. These are carboxylic acids containing exactly one carboxyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassMonocarboxylic acids and derivatives
Direct ParentMonocarboxylic acids and derivatives
Alternative Parents
Substituents
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23